Medicare AdvantagePrior AuthMedium impact
Siliq (brodalumab) injection (Revised)
Humana·Dermatology, Rheumatology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Siliq (brodalumab) injection used to treat moderate to severe plaque psoriasis. Patients must meet specific age, diagnosis, and prior therapy requirements, and the drug has important safety restrictions including a black box warning for suicidal ideation.
Action Required
Before January 1, 2026: Billing team must implement prior authorization requirements for Siliq (brodalumab) prescriptions for Medicare Advantage patients. Providers must verify patients are 18+ years old, have moderate to severe plaque psoriasis diagnosis, and have tried/failed two preferred therapies (Humira, Enbrel, Cosentyx, Skyrizi, Stelara, or Tremfya). Update EMR templates to document these requirements. Claims will be denied without proper prior authorization.